vimarsana.com

Latest Breaking News On - Sagar lonial - Page 1 : vimarsana.com

Lonial Spotlights CAR T-Cell and Off-the-Shelf Treatments in Multiple Myeloma

Sagar Lonial, MD, FACP, details how CAR T-cell therapies and off-the-shelf treatments are improving outcomes for patients with multiple myeloma.

Miami beachUnited statesJanssen biotech incFdad is co burst editionDepartment of hematologyWinship cancer instituteAmerican society of hematologyInternational myeloma society meetingInternational congress on hematologic malignanciesCancer at emory university school of medicineInternational myeloma society annual meetingSagar lonialMedical oncologyBernard gray family chairEmory university schoolWinship cancer

Lonial Reviews 2023 Highlights for Multiple Myeloma, Forecasts 2024 Research Interests

Sagar Lonial, MD, FACP, details additional agents of interest outside CAR T-cell therapies in multiple myeloma including the recently approved agents elranatamab and talquetamab.

Cancer at emory university school of medicineDepartment of hematologySagar lonialNew england journalMedical oncologyBernard gray family chairEmory university schoolRelapsed refractory multiple myelomaCart cell therapiesIdecabtagene vicleucelCiltacabtagene autoleucelPhase 3 karmma trial nct03651128 Phase 3 cartitude 4 trial nct04181827 Bispecifict cell engagers

Quad Regimen for High-Risk Myeloma Produces High Rates of Durable MRD Negativity

Two-thirds of transplant-eligible patients met endpoint with isatuximab/KRd

Nordrhein westfalenCharles bankheadKatjac weiselWinship cancer institute in atlantaGerman multiple myeloma groupInternational staging systemEmory universityUniversity medical center hamburgUniversity medical center hamburg eppendorfSagar lonialWinship cancer instituteMedpage todayClin oncol

Survival on the Upswing in Multiple Myeloma

Hematologists are heralding a new era in multiple myeloma. Experts discuss how times have changed.

United statesTom brokawStanley katzRafael fonsecaJamesr berensonSteve scaliseLos angelesNational cancer instituteWinship cancer instituteAmerican society of hematologyEmory universityNational comprehensive cancer networkCaris life sciencesWest hollywoodSagar lonialWinship cancer

Dr Lonial on the Outcomes of the IKEMA Trial in Relapsed Multiple Myeloma

Sagar Lonial, MD, FACP, discusses the final overall survival analysis of the phase 3 IKEMA trial of isatuximab when combined with carfilzomib and dexamethasone in patients with relapsed multiple myeloma, highlighting the progression-free survival and OS outcomes.

International myeloma society annual meetingEmory university school of medicineDepartment of hematologyWinship cancer institute of emory universitySagar lonialMedical oncologyWinship cancer instituteEmory universityBernard gray family chairEmory university schoolMyeloma society annualOnclive tvMultiple myelomaPhase 3 ikema trialIsatuximab irfc

vimarsana © 2020. All Rights Reserved.